Brief: Bionano and Diagens Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis that Combines OGM and AI
17/04/2024 13:24
April 17 (Reuters) - Bionano Genomics Inc BNGO.O :
* BIONANO AND DIAGENS SIGN PARTNERSHIP TO COMMERCIALIZE THE
FIRST
EVER CLINICAL CYTOGENETIC ANALYSIS THAT COMBINES OGM AND
ARTIFICIAL INTELLIGENCE
* BIONANO GENOMICS INC - DIAGENS WILL BECOME AN ORIGINAL
EQUIPMENT
MANUFACTURING (OEM) PARTNER OF BIONANO IN CHINA
* BIONANO GENOMICS INC - DIAGENS RECEIVED CLASS I
REGISTRATION AND
APPROVAL FOR CO'S OGM REAGENTS FROM CHINA'S NATIONAL MEDICAL
PRODUCTS ADMINISTRATION
Source text for Eikon: ID:nGNX5bZmt1
Further company coverage: BNGO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bionano Genomics
See all newsBionano Genomics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Bionano Genomics Q2 revenue rises on increased clinical adoption
Brief: Bionano Genomics Q2 Revenue USD 8.2 Million
Bionano Genomics, Inc. expected to post a loss of 68 cents a share - Earnings Preview
Bionano Genomics Q1 revenue up 4%, margin improves; to retire convertible debt